INSIGHTS ON UPSTREAM MANUFACTURING

• Evaluating Clone Performance And Cell-Specific Productivity

  See how continuous process monitoring and automated at-line analytics support confident CHO clone ranking, consistent cultivation, and scale-up by connecting pH, viable cell density, and more.

• Enhancing Laboratory Efficiency And Accelerating Time To Market

  Explore how automated screening can accelerate CLD while preserving selection confidence, identifying promising candidates that manual methods may miss, and predicting poor fed-batch performers.

• A Comparison To Traditional Clone Screening Platforms

  See how 46 CHO clones performed across automated, deep-well, and microbioreactor fed-batch cultures, using cell density, viability, and IgG concentration to evaluate clone performance.

• Developing Consistent And Reproducible 3D Spheroid Models

  Improve 3D spheroid consistency by optimizing cell selection, seeding density, and plate geometry. See how practical workflows and comparative data help reduce variability and establish reliability.

• iPSC-Derived MSCs Show Comparable Expansion, EV Production, And Immunomodulatory Potential To Primary MSCs

  8/6/2026

  iPSC-derived MSCs match primary MSCs in expansion, surface marker expression, EV output, and immunomodulatory function, offering a scalable path to standardized cell therapy manufacturing.

• Industrializing iPSC Feed Streams Via Critical Process Parameter And Raw Materials Optimization

  8/6/2026

  Explore how an optimized bioprocess with purpose-designed medium and GMP-compatible reagents achieved 10,000-fold iPSC expansion in under two weeks while maintaining pluripotency and a weekend-free workflow.

• Advanced Analytical Profiling Of MSC-EVs: Tissue- And Donor-Dependent Heterogeneity

  8/6/2026

  Tissue source and donor identity drive measurable differences in MSC-EV quality attributes. See how analytical profiling reveals what varies and why it matters for scalable manufacturing.

• A Unified Development Blueprint For Accelerating Timelines: DNA To DS Bulk Fill In 8.5 months

  8/4/2026

  Learn how early integration of cell line engineering, process development, and analytics compressed a complex antibody program from DNA to drug substance bulk fill in just 8.5 months.